9 Meters Biopharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.011
- Today's High:
- $0.014
- Open Price:
- $0.014
- 52W Low:
- $0.011
- 52W High:
- $5.2
- Prev. Close:
- $0.013
- Volume:
- 85932
Company Statistics
- Market Cap.:
- $1.04 million
- Book Value:
- -0.439
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -111.78%
- Return on Equity TTM:
- -375.64%
Company Profile
9 Meters Biopharma Inc had its IPO on 2016-07-08 under the ticker symbol NMTR.
The company operates in the Healthcare sector and Biotechnology & Medical Research industry. 9 Meters Biopharma Inc has a staff strength of 10 employees.
Stock update
Shares of 9 Meters Biopharma Inc opened at $0.01 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.01 - $0.01, and closed at $0.01.
This is a -15.38% slip from the previous day's closing price.
A total volume of 85,932 shares were traded at the close of the day’s session.
In the last one week, shares of 9 Meters Biopharma Inc have increased by 0%.
9 Meters Biopharma Inc's Key Ratios
9 Meters Biopharma Inc has a market cap of $1.04 million, indicating a price to book ratio of 1.5881 and a price to sales ratio of 0.
In the last 12-months 9 Meters Biopharma Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-43432068. The EBITDA ratio measures 9 Meters Biopharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, 9 Meters Biopharma Inc’s operating margin was 0% while its return on assets stood at -111.78% with a return of equity of -375.64%.
In Q1, 9 Meters Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
9 Meters Biopharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.69 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into 9 Meters Biopharma Inc’s profitability.
9 Meters Biopharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.5929. Its price to sales ratio in the trailing 12-months stood at 0.
9 Meters Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $9.31 million
- Total Liabilities
- $15.58 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
9 Meters Biopharma Inc ended 2024 with $9.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $9.31 million while shareholder equity stood at $-6299205.00.
9 Meters Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $15.58 million in other current liabilities, 1434.00 in common stock, $-226475539.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.94 million and cash and short-term investments were $6.94 million. The company’s total short-term debt was $5,134,760 while long-term debt stood at $0.
9 Meters Biopharma Inc’s total current assets stands at $9.20 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $4.23 million and inventory worth $0.
In 2024, 9 Meters Biopharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, 9 Meters Biopharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.01
- 52-Week High
- $5.2
- 52-Week Low
- $0.011
- Analyst Target Price
- $10.38
9 Meters Biopharma Inc stock is currently trading at $0.01 per share. It touched a 52-week high of $5.2 and a 52-week low of $5.2. Analysts tracking the stock have a 12-month average target price of $10.38.
Its 50-day moving average was $0.18 and 200-day moving average was $0.54 The short ratio stood at 9.97 indicating a short percent outstanding of 0%.
Around 171.3% of the company’s stock are held by insiders while 2353.5% are held by institutions.
Frequently Asked Questions About 9 Meters Biopharma Inc
Similar Industry Stocks (Biotechnology & Medical Research)
Most Active
Top Gainers
Top Losers
About
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.